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CAESAR and the REACH legislation
REACH is the new European legislation for the safe use
of chemicals [1]. It is an enormous initiative, which
requires information for all chemicals which are cur-
rently on the market in Europe in quantities above one
tonne per year. A huge amount of data on each com-
pound is required, and alternative methods to direct
experimentation such as in silico models are listed as
possible sources of this information. In silico models are
those aiming to predict the properties of a chemical
compound on the basis of its chemical structure. How-
ever, this poses the problem of the correct use of these
methods.
C A E S A Ri sau n i q u ep r o j e c tf u n d e db yt h eE u r o p e a n
Commission, dedicated to developing in silico models
specifically designed for the REACH legislation. The leg-
islation has shaped each step of the modeling process.
There are thousands of in silico models which address
new descriptors, new algorithms, or adopt a new
method to predict a certain endpoint. Indeed, activities
in the in silico area exploded in a multitude of aspects.
However, typical in silico models are not suitable for
regulatory purposes, as they have not taken into account
one or more factors essential for validation, quality
assurance, or for a specific application of a given
compound.
The typical approach for in silico modelling is to
develop a model and then propose its use. However, it
is clear that this is a generic approach, not addressing a
specific application.
The REACH requirements
To propose an in silico model for REACH, we must
consider the use of the resulting data within REACH.
REACH promotes the use of all data, but it contains
clear guidelines which should be adopted to ensure
good data quality. In case of in vivo data, specific official
protocols are listed to get high quality data, following
OECD or USEPA procedures. Similarly, when in vitro
data are used, the preferred procedures are identified.
When data have been produced without reference to
the official guidelines, their quality should be evaluated.
Another important point is that for some endpoints
no suitable protocol exists yet.
In case of in silico models and in particular QSAR
models which use quantitative structure-activity rela-
tionships, REACH says that these should be scientifically
valid. We believe that the CAESAR models are scientifi-
cally valid, and we validated them according to a series
of procedures including internal and external validation.
In addition, according to REACH these methods
should be used within their applicability domain. We
developed a number of diverse, innovative, specific tools
to directly assess this. We identified a series of chemical
groups/classes for which the model does not offer opti-
mal performance to be used as a basis for warning.
Furthermore, the models automatically highlight if some
reasons of concern appear for the ideal use of the
model, e.g. boundaries of the descriptor space. Finally,
the model shows the predicted value/category, the
experimental one, and the error of the six most similar
compounds, in relation to the target compound for pre-
diction. Thus, the user has a clear, immediate apprecia-
tion whether similar compounds were included
developing the models and how accurate were their pre-
dictions. A similarity score between compounds is also
provided, to guide the user.
Another aspect mentioned by REACH is that models
should be appropriate for the targets of REACH, such as
classification and labelling, prioritisation and risk assess-
ment. Indeed, we evaluated the nature of the output of
our models, because in some cases continuous values Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156,
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categorical output is needed, for classification and
labelling.
Furthermore, the values produced from QSAR models
should fit as much as possible to the common process
of using data. As we said, data (and most typically we
refer to in vivo data) should be produced according to
good procedures and of checked quality. Thus, also in
the process of model building used within CEASAR, we
dedicated the highest attention of the quality of the data
used as input for our models. The data on chemical
compounds are at the basis of any in silico model.
Within CAESAR we spent about one year checking
data, before starting the modelling procedure. We iden-
tified errors in the existing data collections, in some
cases quite numerous, in other cases minor. We notice
that errors should be checked always for regulatory pur-
poses, not only when building up QSAR models.
Furthermore, we notice that different thresholds exist
depending on the legislation, and this also calls for spe-
cific models.
There are other important parameters to be carefully
evaluated when developing models for regulatory pur-
poses. In particular, false negatives should be minimised.
False negatives are the predictions that a given com-
pound is toxic, while in reality it has toxic potential. It
is clear that this error has a different impact compared
to false positives. Regulators want to avoid false nega-
tives, while false positive are not so critical.
This requires special adapdations and checks to be
incorporated in the models, which are typically not
done when a model is developed or evaluated for other
purposes. Indeed, most typical QSAR models are evalu-
ated using squared errors and differentiation between
false positives and negatives are therefore lost.
CAESAR addressed all these critical factors and goes
beyond the question of scientific quality, which have
been established and discussed eg. in the OECD princi-
ples for QSAR models [2].
Dealing with tools for regulatory purposes, another
important point is the reproducibility of the method or
model. It is obvious that, in the case of a QSAR model
providing different results with different users, the value
of such a model is seriously questionable. We should
mention that some in silico models give different results,
based on expert experience. We believe that for regula-
tory purposes the possibility to get reproducible results
is an advantage. Indeed, if different results can be
obtained, for instance, by the industrial or regulatory
user, or in different countries, this complicates the
assessment of the results, and needs a separate evalua-
tion of the results.
Vice versa, for other purposes, it can be accepted that
the user skill plays a role. For instance, there are
complex programs which require careful optimisation of
certain parameters, such as three-dimensional confor-
mation. Experts are requested to run these programs
properly. The use of these complex tools is more suita-
ble within industry for their aims, such as drug design,
where the role of the expert is usually fundamental.
Models for stakeholders
Within CAESAR we dedicated special attention to the
users and the access of the models. Thus, we preferred
to develop models which are simple to used. We dedi-
cated special studies to facilitate the user. A graphical
interface guides the user through three easy steps. CAE-
SAR is intuitive and in this it has been preferred within
a training course when different models have been pre-
sented. The particular application of REACH needs to
keep into account the stakeholders. This means that the
issues to be evaluated are not only theoretical but prac-
tical. If a certain model requires special experience, this
is a barrier.
We preferred to follow an approach such as that used
by the US EPA. The same easy model is available to all
stakeholders: industry and regulators. Thus, the same
rules are known, the model is transparent and
reproducible.
The CAESAR models can be used to process a large
number of chemicals in batch. This fact also increases
the versatility and usability, and thus the impact of the
models. Indeed, the CAESAR models can be used to
screen a large number of compounds, for instance for
prioritisation, which is a target mentioned by REACH,
and particularly useful for regulatory bodies such as the
European Chemicals Agency. Recently, it was found that
the number of chemicals which potentially must be eval-
uated, on the basis of the preregistration of the chemical
substances, is much higher than expected. This higher
number may mean that the actual number of substances
checked may be low. From this perspective, the avail-
ability of tools such as those developed by CAESAR is
highly beneficial for regulators, as they can easily and
rapidly process a large number of compounds.
Thus the potential impact of CAESAR’sm o d e l ,i f
adopted by regulators for screening purposes, is that
regulators could easily process all compounds, and iden-
tify critical issues. This can improve the evaluation of
the chemicals in the European market, and eventually
minimise the possibility of toxic compounds making
their way onto the market.
Furthermore, the CAESAR models are free. Indeed,
some of the addressed endpoints are expensive to study
experimentally. There have been critical comments that
REACH will impose a high cost on industry, but the use
of CAESAR’s model can solve this issue, for the specific
endpoints we studied.
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can be pro-active, to anticipate future potential pro-
blems related to certain chemical structures. This is a
further useful possibility of larger use, and thus models
can have an impact on industry, which can run the
models when planning new compounds, and assess in
advance if a certain structure may present critical
aspects. As a result, industry will have a powerful tool
to produce safer chemicals, which is the final target of
REACH.
Since the models are free, they can be easily used by
non-governmental organisations interested in safety
assessment.
The CAESAR models are available on the internet
http://www.caesar-project.eu. This facilitates their access
on a worldwide basis. We will describe more in detail
the software used to implement selected models devel-
oped within CAESAR in the five papers of this issue.
The five CAESAR models
CAESAR developed new QSAR models specific for
REACH for these endpoints:
￿ bioconcentration in fish,
￿ skin sensitisation,
￿ mutagenicity,
￿ carcinogenicity,
￿ developmental toxicity.
Many tens of different models have been developed
for each endpoint, and we implemented some of the
best ones in the internet platform. The papers in this
i s s u ed e s c r i b es o m eo ft h e s eb e s tm o d e l s ,a n dt h e i r
implementation on the internet.
All of them match the criteria described above. We do
not consider these models as the ultimate solution, but
we believe they represent a major improvement in the
current scenario for the reasons described, and because
the results of these models have been assessed as being
as good as or more frequently better than those
obtained with other models.
We believe that in some cases the models can replace
the current method, and in all cases the information
obtained from the model is a valuable supplement to
other sources of data. This depends on the endpoint
and on the chemical.
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